These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 31941438)

  • 1. Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model.
    Lukkes JL; Drozd HP; Fitz SD; Molosh AI; Clapp DW; Shekhar A
    J Neurodev Disord; 2020 Jan; 12(1):2. PubMed ID: 31941438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHD.
    Pillidge K; Porter AJ; Dudley JA; Tsai YC; Heal DJ; Stanford SC
    Br J Pharmacol; 2014 Oct; 171(20):4785-96. PubMed ID: 25074741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of guanfacine improves food-motivated impulsive choice behavior primarily via direct stimulation of postsynaptic α
    Nishitomi K; Yano K; Kobayashi M; Jino K; Kano T; Horiguchi N; Shinohara S; Hasegawa M
    Behav Brain Res; 2018 Jun; 345():21-29. PubMed ID: 29476896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
    Michelini G; Lenartowicz A; Vera JD; Bilder RM; McGough JJ; McCracken JT; Loo SK
    J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):415-426. PubMed ID: 35963559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder.
    Kawaura K; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2014 Aug; 270():349-56. PubMed ID: 24882610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of α-2A adrenergic receptor agonist on time and risk preference in primates.
    Kim S; Bobeica I; Gamo NJ; Arnsten AF; Lee D
    Psychopharmacology (Berl); 2012 Jan; 219(2):363-75. PubMed ID: 21979441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ; Perry CM
    Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).
    Alamo C; López-Muñoz F; Sánchez-García J
    Actas Esp Psiquiatr; 2016 May; 44(3):107-12. PubMed ID: 27254403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noradrenergic α2A-receptor stimulation in the ventral hippocampus reduces impulsive decision-making.
    Abela AR; Chudasama Y
    Psychopharmacology (Berl); 2014 Feb; 231(3):521-31. PubMed ID: 24062084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Rizzo R; Martino D
    Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile exposure to methylphenidate and guanfacine in rats: effects on early delay discounting and later cocaine-taking behavior.
    Freund N; Jordan CJ; Lukkes JL; Norman KJ; Andersen SL
    Psychopharmacology (Berl); 2019 Feb; 236(2):685-698. PubMed ID: 30411140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
    Ota T; Yamamuro K; Okazaki K; Kishimoto T
    Drug Des Devel Ther; 2021; 15():1965-1969. PubMed ID: 34007156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha 2A adrenergic receptor agonist, guanfacine, attenuates cocaine-related impairments of inhibitory response control and working memory in animal models.
    Terry AV; Callahan PM; Schade R; Kille NJ; Plagenhoef M
    Pharmacol Biochem Behav; 2014 Nov; 126():63-72. PubMed ID: 25242808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder.
    Loo SK; Bilder RM; Cho AL; Sturm A; Cowen J; Walshaw P; Levitt J; Del'Homme M; Piacentini J; McGough JJ; McCracken JT
    J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):674-682.e1. PubMed ID: 27453081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noradrenergic contributions to cue-driven risk-taking and impulsivity.
    Chernoff CS; Hynes TJ; Winstanley CA
    Psychopharmacology (Berl); 2021 Jul; 238(7):1765-1779. PubMed ID: 33649970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Connor DF; Rubin J
    Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
    Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
    J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Pharmacologic Considerations for Guanfacine Use in Very Young Children.
    Black BT; Soden SE; Kearns GL; Jones BL
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):498-504. PubMed ID: 26894823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior.
    Freeman ZT; Rice KA; Soto PL; Pate KA; Weed MR; Ator NA; DeLeon IG; Wong DF; Zhou Y; Mankowski JL; Zink MC; Adams RJ; Hutchinson EK
    Transl Psychiatry; 2015 May; 5(5):e567. PubMed ID: 25989141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.